• Prevention of perinatal loss: towards personalized medicine 

Prevention of perinatal loss: towards personalized medicine 

PERINATOLOGIYA I PEDIATRIYA.2016.1(65):59-65;doi 10.15574/PP.2016.65.59 
 

Prevention of perinatal loss: towards personalized medicine 
 

Medvedev M. V., Davydova Yu. V.

SI «Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine»

SI «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine», Kiev 
 

The literature review on the prevention of preterm labor is carried out. Preterm labor is the actual problem of modern obstetrics due to the impact on maternal and child health. It is affects the level of perinatal morbidity, disability and infant mortality. Preterm labor occupies a dominant position in the structure of perinatal losses. Introduction of the prophylactic modern technologies of the preterm labor using micronized progesterone containing preparations allows clearly reduce their frequency in a number of clinics that use the destination progesterone protocol for ultrasound cervical length less than 25 mm, as well as in women with preterm labor in history. 
 

Key words: premature labor, prevention. 
 

REFERENCES

1. Holianovskyi V. 2015. Prohesteron: «za» i «proty». Z turbotoiu pro zhinku. 60; 3: 54—58.

2. Ziyadinov AA, Anikin SS, Ryibalka AN. 2012. Riski prezhdevremennyih rodov. Tavricheskiy mediko-biologicheskiy vestnik. 15; 2; P2: 257—260.

3. Lekhan VM, Hinzburh VH. 2012. Perynatalna smertnist v Ukraini: dosiahnennia ta problemy. Ukraina. Zdorovia natsii. 21;1: 15—25.

4. Agyeman A.A. Ofori-Asenso R. 2015. Perspective: Does personalized medicine hold the future for medicine? J Pharm Bioallied Sci. 7; 3: 239—244. http://dx.doi.org/10.4103/0975-7406.160040; PMid:26229361 PMCid:PMC4517329

5. Al-Salam Z. 2012. Antenatal magnesium sulfate decreases risk of cerebral palsy J Clin Neonatol. 1; 1: 13—15. http://dx.doi.org/10.4103/2249-4847.92235; PMid:24027676 PMCid:PMC3761983

6. Arisoy R, Yayla M. 2012. Transvaginal sonographic evaluation of the cervix in asymptomatic singleton pregnancy and management options in short cervix. J Pregnancy: 2016—2028. http://dx.doi.org/10.1155/2012/201628

7. Smith LK, Draper ES, Evans TA et al. 2015. Associations between late and moderately preterm birth and smoking, alcohol, drug use and diet: a population-based case-cohort study. Arch Dis Child Fetal Neonatal Ed. 100; 6: F486—491. http://dx.doi.org/10.1136/archdischild-2014-307265

8. Sosa CG, Althabe F, Belizan JM et al. 2015. Bed rest in singleton pregnancies for preventing preterm birth. Cochrane Database Syst Rev. 3: CD003581. http://dx.doi.org/10.1002/14651858.cd003581.pub3

9. Behrman RE. 2007. Preterm Birth: Causes, Consequences, and Prevention. RE Behrman, AS Butler (editors). Washington (DC).

10. Berhan Y, Berhan A. 2014. Commentary: Actions in the pipeline and the way forward to reduce maternal and perinatal mortality in Ethiopia. Ethiop J Health Sci. 24: 149—168. http://dx.doi.org/10.4314/ejhs.v24i0.13S; PMid:25489189 PMCid:PMC4249202

11. Bhakoo ON, Kumar R. 1990. Action plan to reduce perinatal mortality. ICCW News Bull. 38; 2: 11—14. PMid:12316585

12. Bombard Y. 2015. Translating personalized genomic medicine into clinical practice: evidence, values, and health policy. Genome: 1—7. http://dx.doi.org/10.1139/gen-2015-0145

13. Conde-Agudelo A, Romero R. 2009. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol. 200; 6: 595—609. http://dx.doi.org/10.1016/j.ajog.2009.04.005; PMid:19482113 PMCid:PMC3459676

14. Doyle LW. 2012. Antenatal magnesium sulfate and neuroprotection. Curr Opin Pediatr. 24; 2: 154—159. http://dx.doi.org/10.1097/MOP.0b013e3283504da1; PMid:22227787

15. Crowther CA, Hiller JE, Doyle LW et al. 2003. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. Australasian Collaborative Trial of Magnesium Sulphate Collaborative Group. JAMA. 290; 20: 2669—2676. http://dx.doi.org/10.1001/jama.290.20.2669; PMid:14645308

16. El-Refaie W, Abdelhafez MS, Badawy A. 2015.Vaginal progesterone for prevention of preterm labor in asymptomatic twin pregnancies with sonographic short cervix: a randomized clinical trial of efficacy and safety. Arch Gynecol Obstet.

17. Schindler AE, Carp H, Druckmann R et al. 2015. European Progestin Club Guidelines for prevention and treatment of threatened or recurrent (habitual) miscarriage with progestogens. Gynecol Endocrinol. 31; 6: 447—449. http://dx.doi.org/10.3109/09513590.2015.1017459; PMid:25976550

18. How HY, Sibai BM. 2009. Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety. Ther Clin Risk Manag. 5; 1: 55—64.

19. Yang S, Reid G, Challis JR et al. 2015. Is there a role for probiotics in the prevention of preterm birth? Front Immunol. 6: 62. http://dx.doi.org/10.3389/fimmu.2015.00062; PMid:25741339 PMCid:PMC4330906

20. Kapil U. 1989. Strategies to reduce perinatal and neonatal mortality. Indian Pediatr. 26; 3: 301—302. PMid:2753563

21. Madarek EO, Najati N. 2003. The effect of glucocorticoid therapy in preventing early neonatal complications in preterm delivery. J Perinat Med. 31; 5: 441—443. http://dx.doi.org/10.1515/JPM.2003.069; PMid:14601269

22. Doyle LW, Crowther CA, Middleton P et al. 2009. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev. 1: CD004661. http://dx.doi.org/10.1002/14651858.cd004661.pub3

23. Marret S, Marpeau L, Zupan-Simunek V et al. 2007. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. Group Premag trial. BJOG. 114; 3: 310—318. http://dx.doi.org/10.1111/j.1471-0528.2006.01162.x; PMid:17169012

24. Martinez de Tejada B, Karolinski A, Ocampo MC et al. 2015. Prevention of preterm delivery with vaginal progesterone in women with preterm labour (4P): randomised double-blind placebo-controlled trial. BJOG. 122; 1: 80—91. http://dx.doi.org/10.1111/1471-0528.13061; PMid:25209926

25. Mercer BM. 2003. Preterm premature rupture of the membranes. Obstet Gynecol. 101; 1: 178-193. http://dx.doi.org/10.1097/00006250-200301000-00033http://dx.doi.org/10.1016/S0029-7844(02)02366-9

26. Mittendorf R, Dammann O, Lee KS. 2006. Brain lesions in newborns exposed to high-dose magnesium sulfate during preterm labor. J Perinatol. 26; 1: 57—63. http://dx.doi.org/10.1038/sj.jp.7211419; PMid:16319938

27. Norwitz ER. 2015. Clarifying when to recommend progesterone to prevent preterm birth: clear as mud. BJOG. 122; 1: 92.

28. O'Brien JM. 2011. 17-hydroxyprogesterone caproate, progesterone, preterm birth prevention, and safety: who decides? Someone should. Am J Obstet Gynecol. 204; 5: e16—7; author reply e17.

29. O'Brien JM. 2013. Medication safety is still an issue in obstetrics 50 years after the Kefauver-Harris amendments: the case of progestogens. Ultrasound Obstet Gynecol. 42; 3: 247—253. http://dx.doi.org/10.1002/uog.12456; PMid:23495199

30. O'Brien JM. 2012. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment. Am J Perinatol. 29; 9: 665—672. http://dx.doi.org/10.1055/s-0032-1316444; PMid:22773279

31. Oddie S, Tuffnell DJ, McGuire W. 2015. Antenatal magnesium sulfate: Neuro-protection for preterm infants. Arch Dis Child Fetal Neonatal Ed. 100; 6: F553—557. http://dx.doi.org/10.1136/archdischild-2014-307655

32. Markham KB, Walker H, Lynch CD et al. 2014. Preterm birth rates in a prematurity prevention clinic after adoption of progestin prophylaxis. Obstet Gynecol. 123; 1: 34—39. http://dx.doi.org/10.1097/AOG.0000000000000048; PMid:24463661

33. Romero R, Yeo L, Chaemsaithong P et al. 2014. Progesterone to prevent spontaneous preterm birth. Semin Fetal Neonatal Med. 19; 1: 15—26. http://dx.doi.org/10.1016/j.siny.2013.10.004; PMid:24315687 PMCid:PMC3934502

34. Da Fonseca EB, Bittar RE, Carvalho MH et al. 2003. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 188; 2: 419—424. http://dx.doi.org/10.1067/mob.2003.41; PMid:12592250

35. Rahman A, Moran A, Pervin J et al. 2011. Effectiveness of an integrated approach to reduce perinatal mortality: recent experiences from Matlab, Bangladesh. BMC Public Health. 11: 914. http://dx.doi.org/10.1186/1471-2458-11-914; PMid:22151276 PMCid:PMC3257323

36. Seelbach-Goebel B. 2013. Antibiotic Therapy for Premature Rupture of Membranes and Preterm Labor and Effect on Fetal Outcome. Geburtshilfe Frauenheilkd. 73; 12: 1218—1227. http://dx.doi.org/10.1055/s-0033-1360195; PMid:24771902 PMCid:PMC3964356

37. Magee L, Sawchuck D, Synnes A et al. 2011. SOGC Clinical Practice Guideline. Magnesium sulphate for fetal neuroprotection. J Obstet Gynecol Can. 33; 5: 516—529. http://dx.doi.org/10.1016/S1701-2163(16)34886-1

38. Stark MJ, Hodyl NA, Andersen CC. 2015. Effects of antenatal magnesium sulfate treatment for neonatal neuro-protection on cerebral oxygen kinetics. Pediatr Res. 78; 3: 310—314. http://dx.doi.org/10.1038/pr.2015.96; PMid:25985294

39. Kimber-Trojnar Z, Leszczynska-Gorzelak B, Marciniak B et al. 2010. Tocolytic therapy in threatened preterm labor. Gynecol Pol. 81; 2: 120—124.

40. Gyetvai K, Hannah ME, Hodnett ED et al. 1999. Tocolytics for preterm labor: a systematic review. Obstet Gynecol. 94; 5; Pt 2: 869—877. http://dx.doi.org/10.1097/00006250-199911001-00043http://dx.doi.org/10.1016/S0029-7844(99)00329-4

Содержание журнала Full text of article